{
    "organizations": [],
    "uuid": "ded001d1e37b0973f506cb22f8f1b33c6cafe070",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-european-medicine/brief-astrazeneca-says-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-idUSFWN1RG01M",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Says European Medicines Agency Accepts Regulatory Submission For Lynparza In Brca-Mutated, Her2 Negative Metastatic",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - AstraZeneca PLC:\n* EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA IN BRCA-MUTATED, HER2-NEGATIVE METASTATIC\n* CO AND MERCK ANNOUNCES EUROPEAN MEDICINES AGENCY HAS VALIDATED FOR REVIEW MARKETING AUTHORISATION APPLICATION FOR LYNPARZA (OLAPARIB) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-03T14:47:00.000+03:00",
    "crawled": "2018-04-04T12:41:11.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "european",
        "medicine",
        "agency",
        "accepts",
        "regulatory",
        "submission",
        "lynparza",
        "metastatic",
        "co",
        "merck",
        "announces",
        "european",
        "medicine",
        "agency",
        "validated",
        "review",
        "marketing",
        "authorisation",
        "application",
        "lynparza",
        "olaparib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}